All Articles

Immunotherapy and targeted therapy have resulted in improved survival rates in patients with NSCLC over the past decade.

Multidisciplinary tumor board members work closely to make the best clinical decisions for their patients with cancer to improve patient and institutional outcomes. Their decisions should be based on the clinical data of each patient in line with their own clinical and institutional guidelines.

Recently released results using liquid biopsy shows KRAS G12C mutation in patients with NSCLC can be lost or acquired at progressive disease.

Social listening can offer investigators valuable information about unmet patient needs and concerns regarding their cancer treatment and to direct future research.

Researchers found a large underrepresentation gap among minority populations across major cancer types in clinical trials.

Improved understanding of self-care behaviors in patients with cancer who take oral anticancer medications can help healthcare professionals support patient medication adherence.

Providing quality care requires understanding the disease factors, clinical presentation, and management strategies for immunotherapy-induced cytokine release syndrome with acute lymphoblastic leukemia treatment.

An overview of the clinical presentation, management approaches, and clinical practice guidelines for immunotherapy-related neurotoxicity in acute lymphoblastic leukemia treatment is presented.

Clinicians should recognize the prognostic importance of minimal residual disease testing and its implications for treatment pathways in acute lymphoblastic leukemia.

Navigating the complexities of acute lymphoblastic leukemia treatment requires a multidisciplinary team approach to the management of multiple care needs in inpatient and outpatient settings.